vs
Celldex Therapeutics, Inc.（CLDX）与TRINITY BIOTECH PLC（TRIB）财务数据对比。点击上方公司名可切换其他公司
TRINITY BIOTECH PLC的季度营收约是Celldex Therapeutics, Inc.的254.6倍（$30.5M vs $120.0K）。TRINITY BIOTECH PLC净利率更高（-33.0% vs -67764.2%，领先67731.2%）。TRINITY BIOTECH PLC自由现金流更多（$-4.1M vs $-65.2M）
Celldex Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性癌症和罕见免疫疾病的靶向免疫疗法，管线涵盖抗体药物偶联物、单克隆抗体等创新疗法，致力于满足大量未被满足的临床医疗需求。
Trinity Biotech PLC是一家全球体外诊断企业，研发、生产和销售适用于临床实验室与床旁检测场景的诊断试剂盒及配套系统，产品线覆盖糖尿病管理、传染病、心脏健康、自身免疫疾病等领域，主要市场包括北美、欧洲及全球新兴经济体。
CLDX vs TRIB — 直观对比
营收规模更大
TRIB
是对方的254.6倍
$120.0K
净利率更高
TRIB
高出67731.2%
-67764.2%
自由现金流更多
TRIB
多$61.2M
$-65.2M
损益表 — Q4 2025 vs Q2 2024
| 指标 | | |
|---|---|---|
| 营收 | $120.0K | $30.5M |
| 净利润 | $-81.3M | $-10.1M |
| 毛利率 | — | 36.8% |
| 营业利润率 | -72628.3% | -23.2% |
| 净利率 | -67764.2% | -33.0% |
| 营收同比 | -89.8% | — |
| 净利润同比 | -72.7% | — |
| 每股收益（稀释后） | $-1.23 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDXTRIB
| Q4 25 | $120.0K | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $730.0K | — | ||
| Q1 25 | $695.0K | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $2.5M | $30.5M | ||
| Q1 24 | $156.0K | — |
净利润CLDXTRIB
| Q4 25 | $-81.3M | — | ||
| Q3 25 | $-67.0M | — | ||
| Q2 25 | $-56.6M | — | ||
| Q1 25 | $-53.8M | — | ||
| Q4 24 | $-47.1M | — | ||
| Q3 24 | $-42.1M | — | ||
| Q2 24 | $-35.8M | $-10.1M | ||
| Q1 24 | $-32.8M | — |
毛利率CLDXTRIB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 36.8% | ||
| Q1 24 | — | — |
营业利润率CLDXTRIB
| Q4 25 | -72628.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -8747.5% | — | ||
| Q1 25 | -9027.2% | — | ||
| Q4 24 | -4768.3% | — | ||
| Q3 24 | -1633.5% | — | ||
| Q2 24 | -1854.2% | -23.2% | ||
| Q1 24 | -26030.8% | — |
净利率CLDXTRIB
| Q4 25 | -67764.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -7753.4% | — | ||
| Q1 25 | -7740.4% | — | ||
| Q4 24 | -4007.8% | — | ||
| Q3 24 | -1320.0% | — | ||
| Q2 24 | -1434.8% | -33.0% | ||
| Q1 24 | -21030.8% | — |
每股收益（稀释后）CLDXTRIB
| Q4 25 | $-1.23 | — | ||
| Q3 25 | $-1.01 | — | ||
| Q2 25 | $-0.85 | — | ||
| Q1 25 | $-0.81 | — | ||
| Q4 24 | $-0.71 | — | ||
| Q3 24 | $-0.64 | — | ||
| Q2 24 | $-0.54 | — | ||
| Q1 24 | $-0.56 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $518.6M | $5.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $527.2M | $-29.4M |
| 总资产 | $583.0M | $94.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLDXTRIB
| Q4 25 | $518.6M | — | ||
| Q3 25 | $583.2M | — | ||
| Q2 25 | $630.3M | — | ||
| Q1 25 | $673.3M | — | ||
| Q4 24 | $725.3M | — | ||
| Q3 24 | $756.0M | — | ||
| Q2 24 | $802.3M | $5.3M | ||
| Q1 24 | $823.8M | — |
股东权益CLDXTRIB
| Q4 25 | $527.2M | — | ||
| Q3 25 | $598.4M | — | ||
| Q2 25 | $655.4M | — | ||
| Q1 25 | $703.0M | — | ||
| Q4 24 | $747.0M | — | ||
| Q3 24 | $785.9M | — | ||
| Q2 24 | $813.7M | $-29.4M | ||
| Q1 24 | $838.6M | — |
总资产CLDXTRIB
| Q4 25 | $583.0M | — | ||
| Q3 25 | $648.4M | — | ||
| Q2 25 | $692.4M | — | ||
| Q1 25 | $739.5M | — | ||
| Q4 24 | $792.3M | — | ||
| Q3 24 | $823.2M | — | ||
| Q2 24 | $845.6M | $94.4M | ||
| Q1 24 | $868.8M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-63.9M | $-3.9M |
| 自由现金流经营现金流 - 资本支出 | $-65.2M | $-4.1M |
| 自由现金流率自由现金流/营收 | -54350.8% | -13.3% |
| 资本支出强度资本支出/营收 | 1067.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-213.7M | $-4.1M |
8季度趋势，按日历期对齐
经营现金流CLDXTRIB
| Q4 25 | $-63.9M | — | ||
| Q3 25 | $-48.6M | — | ||
| Q2 25 | $-44.0M | — | ||
| Q1 25 | $-54.4M | — | ||
| Q4 24 | $-32.5M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-29.3M | $-3.9M | ||
| Q1 24 | $-40.6M | — |
自由现金流CLDXTRIB
| Q4 25 | $-65.2M | — | ||
| Q3 25 | $-49.1M | — | ||
| Q2 25 | $-44.7M | — | ||
| Q1 25 | $-54.6M | — | ||
| Q4 24 | $-33.2M | — | ||
| Q3 24 | $-55.9M | — | ||
| Q2 24 | $-29.6M | $-4.1M | ||
| Q1 24 | $-41.0M | — |
自由现金流率CLDXTRIB
| Q4 25 | -54350.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6127.8% | — | ||
| Q1 25 | -7861.4% | — | ||
| Q4 24 | -2828.3% | — | ||
| Q3 24 | -1751.2% | — | ||
| Q2 24 | -1185.0% | -13.3% | ||
| Q1 24 | -26270.5% | — |
资本支出强度CLDXTRIB
| Q4 25 | 1067.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 99.7% | — | ||
| Q1 25 | 38.1% | — | ||
| Q4 24 | 64.3% | — | ||
| Q3 24 | 17.1% | — | ||
| Q2 24 | 11.0% | 0.5% | ||
| Q1 24 | 220.5% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
